Evolving Therapeutic Approaches and Shifting Paradigms in the Treatment of Multiple Myeloma
Over the last decade, advances made in the understanding and therapeutic targeting of biologic and genetic mechanisms involved in the pathogenesis of multiple myeloma (MM) have steadily enhanced clinical outcomes. While multiple myeloma (MM) remains incurable, survival benefits afforded by new therapeutic and management strategies are leading to a significant present day paradigm shift of consideration of MM as a chronic disease to be managed, rather than an inevitably fatal cancer.
This activity brings leading myeloma experts together to discuss some of the most important issues in myeloma today, including current and future practice for patients with smoldering myeloma, the development of novel targeted therapies; evolving clinical paradigms on timing of HDT-ASCT and continuous /maintenance therapy; the evolution of treatment strategies to overcome acquired resistance to therapy including new combination therapies and new classes of therapeutics never before used in multiple myeloma
This educational activity is designed to meet the educational needs of hematologists, medical oncologists and other healthcare professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physicians’ assistants, etc.) involved and/or interested in the therapeutic management of patients with MM.
After completing this program, participants should be able to:
1. Describe current treatment strategies and supporting rationales for the individualized management of transplant-eligible, as well as elderly multiple myeloma patients throughout the lifecycle of the disease
2. Assess the shifting treatment paradigms of multiple myeloma including emerging regimens used in smoldering myeloma, primary therapy, consolidation therapy, maintenance therapy, and relapsed/ refractory disease
3. Evaluate finalized and ongoing clinical trial data utilizing standard of care and/or investigational therapies that have the potential to enhance clinical outcomes in newly diagnosed, elapsed/refractory, and non-transplant eligible
4. Summarize emerging new classes of therapeutics and potential combinations, primarily in the relapsed/ refractory setting
Rush University is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. Rush University designates this live activity for one (1) Continuing Education credit(s).
This activity is being presented without bias and with commercial support.
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1 hour (0.1 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. UAN # 0761-9999-16-107-L01-P
Rush University Medical Center
Jatin J. Shah, MD (Chair)
The University of Texas MD Anderson Cancer Center
Rafael Fonseca, MD
Ola Landgren, MD
Memorial Sloan Kettering Cancer Center
New York, New York
Philip McCarthy, MD
Roswell Park Cancer Institute
Johnathan L. Kaufman, MD
Winship Cancer Institute of Emory University